• Male participants with histologically confirmed adenocarcinoma of the prostate

• High-risk / very high-risk status per NCCN guidelines

• ECOG performance status 0 to 1

• Regional lymph nodes are allowed.

• Agree to use contraception during the treatment period and for at least 120 days after the last dose of study intervention and refrain from donating sperm during this period.

• Ability to understand and the willingness to sign a written informed consent document.

• Adequate organ and marrow function

• Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation is ≤90 days prior to the date of registration

• Prior 5-alpha reductase inhibitor (for example, finasteride) for prostatic hypertrophy is allowed if discontinued at least 60 days prior to registration.

• Known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification.